Protons against cancer: New research beamline for innovative radiotherapies
Prof. Dr Judith Reindl and PhD student Aikaterini Rousseti (from left to right) from the University of the Bundeswehr Munich present the experimental station for biological samples which is installed at the new Minibee beamline at HZB. © Kevin Fuchs / HZB
Magnetic quadrupoles focus the proton beam in front of the experiment platform. © Kevin Fuchs / HZB
Together with the University of the Bundeswehr Munich, the HZB has set up a new beamline for preclinical research. It will enable experiments on biological samples on innovative radiation therapies with protons.
The proton accelerator at the Helmholtz-Zentrum Berlin (HZB) has been used for about 25 years to combat certain types of eye tumours. So far, over 4800 people have benefited from proton eye tumour therapy, which is carried out in collaboration with Charité – Universitätsmedizin Berlin.
Now, the proton accelerator at HZB also offers the option of conducting preclinical research: A mini-beamline for preclinical experiments (Minibee) has been set up for this purpose together with the University of the Bundeswehr in Munich. The HZB's Proton Therapy Department has built the beam guidance and control system for the minibeams. The University of the Bundeswehr in Munich, with Prof. Judith Reindl from the Institute of Applied Physics and Measurement Technology and the Section of Biomedical Radiation Physics, installed a platform for image-guided irradiation of biological samples. This will enable joint experiments on radiobiology and innovative radiation therapy in the future.
‘At Minibee, we can use medical research to investigate how changes in parameters and settings of the proton beam affect the treatment,’ says Judith Reindl. Among other things, Minibee is designed to generate ultrashort proton flashes (FLASH therapy) or needle-fine radiation (beamlets). ‘Our aim is to develop new methods that effectively destroy tumours while providing even better protection for healthy tissue,’ says Prof. Dr. Andrea Denker, head of the Department of Proton Therapy at HZB.
- Science in Berlin: collaborative, diverse, innovative, internationalScience is a key social and economic factor for Berlin. It creates jobs and adds value, attracts talent from all over the world, and enriches city life. To ensure that Berlin remains one of the world’s leading centres of science in the future, science must feature even more prominently on the political agenda. This is what BR50 stands for: over 50 non-university research institutions, including the HZB, are joining forces in this network. Following the election in Berlin, BR50 is now addressing politicians with a position paper, accompanied by the campaign “𝗪𝗶𝗿 𝗳𝗼𝗿𝘀𝗰𝗵𝗲𝗻 𝗳ü𝗿 𝗕𝗲𝗿𝗹𝗶𝗻.”
- Does African Architecture exist?The world’s first Pan-African Architecture Biennale took place this September in Nairobi, Kenya. People from the worlds of architecture, art, academia and politics from 54 African countries and the diaspora had travelled to Nairobi to exchange ideas on traditional and contemporary building methods, materials, experiences and projects. Samira Aden co-organised this biennial as lead curator. We spoke to her about it.
- Nanosilver as an electrocatalyst for CO₂ reductionVia electrolysis, CO2 can be reduced to CO, a raw material for further chemical products such as fuels. Within the GreenQuest Project, an internation team led by HZB chemist Prashanth Menezes has now systematically investigated catalyst layers made of silver nanoparticles, varying both the size of the particles and their density. The best yield was achieved with nanoparticles with diameters of around 10 nm, which were loosely distributed. Furthermore, they demonstrated how the economic efficiency of the electrochemical cell can be enhanced by integrating an additional chemical reaction at the anode, enabling the simultaneous production of a valuable formic acid, hydrogen, and CO in one device.